Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:38:03 EDT Thu 19 Sep 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:PCVX - VAXCYTE INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PCVX - Q0.197.86·186.460.2116.54    119.50  44.20Sep 18Sep 1115 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-11 16:05U:PCVXNews ReleaseVaxcyte to Present at the 2024 Cantor Global Healthcare Conference
2024-09-06 16:06U:PCVXNews ReleaseVaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-09-04 23:59U:PCVXNews ReleaseVaxcyte Announces Pricing of $1.3 Billion Public Offering
2024-09-03 16:02U:PCVXNews ReleaseVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
2024-09-03 07:08U:PCVXNews ReleaseVaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
2024-09-02 18:41U:PCVXNews ReleaseVaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
2024-08-06 16:05U:PCVXNews ReleaseVaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-07-02 08:30U:PCVXNews ReleaseVaxcyte Appoints John Furey to Board of Directors
2024-05-08 16:05U:PCVXNews ReleaseVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
2024-04-02 16:06U:PCVXNews ReleaseVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-04 08:30U:PCVXNews ReleaseVaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
2024-02-27 16:01U:PCVXNews ReleaseVaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-15 16:05U:PCVXNews ReleaseVaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-02-02 18:39U:PCVXNews ReleaseVaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2024-02-01 16:06U:PCVXNews ReleaseVaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
2024-01-30 23:38U:PCVXNews ReleaseVaxcyte Announces Pricing of $750 Million Public Offering
2024-01-30 16:01U:PCVXNews ReleaseVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
2024-01-29 08:31U:PCVXNews ReleaseVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
2024-01-16 16:01U:PCVXNews ReleaseVaxcyte Appoints Whitney Jones as Chief People Officer
2024-01-04 16:02U:PCVXNews ReleaseVaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise